ChemSpider 2D Image | OMBRABULIN HYDROCHLORIDE | C21H27ClN2O6

OMBRABULIN HYDROCHLORIDE

  • Molecular FormulaC21H27ClN2O6
  • Average mass438.902 Da
  • Monoisotopic mass438.155762 Da
  • ChemSpider ID5293601

  • Double-bond stereo - Double-bond stereo

    defined stereocentres - 1 of 1 defined stereocentres

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

253426-24-3 [RN]
N-{2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenyl}-L-serinamide hydrochloride (1:1) [ACD/IUPAC Name]
N-{2-Méthoxy-5-[(Z)-2-(3,4,5-triméthoxyphényl)vinyl]phényl}-L-sérinamide, chlorhydrate (1:1) [French] [ACD/IUPAC Name]
N-{2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenyl}-L-serinamidhydrochlorid (1:1) [German] [ACD/IUPAC Name]
OMBRABULIN HYDROCHLORIDE
Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]-, hydrochloride (1:1), (2S)-
Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]-, (2S)-, hydrochloride (1:1) [ACD/Index Name]
(2S)-2-amino-3-hydroxy-N-[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide;hydrochloride
181816-48-8 [RN]
253426-24-3 (HCl)
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

KXZ9NDO6H0 [DBID]
AC-7700 [DBID]
AVE-8062 [DBID]
UNII:KXZ9NDO6H0 [DBID]
UNII-KXZ9NDO6H0 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. MedChem Express HY-18256
      Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. CA-4-P induces G2/M arrest, thus bringing about cell death by either mitotic catastrophe or apoptosis. Ombrabulin is a vascular disrupting agent.;Target: Differently from CA-4-P, Ombrabulin does not act directly on the tumor vessels but instead causes constriction of the arterioles, resulting in complete downstream arrest of the blood flow and tumor. Recently, Ombrabulin in combination with cisplatin was used in a phase III clinical trial for patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy, significantly improving progression-free survival. However, this improvement was not clinically relevant, despite being statistically significant. [1] Ombrabulin disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour activity w MedChem Express HY-18256
      Others MedChem Express HY-18256

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site


Advertisement